Denny Lanfear, Coherus BioSciences CEO
December 3, 2024 01:44 PM EST
Deals
Pharma

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Nicole DeFeudis

Editor

Co­herus Bio­Sciences’ stock surged on Tues­day af­ter the com­pa­ny an­nounced plans to sell off the last biosim­i­lar in its port­fo­lio.

In­tas Phar­ma­ceu­ti­cals

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Ex­clu­sive: Joe Jimenez's Adi­tum Bio rings in new year with $428M third fund

Eu­ro­pean macro­cy­cle start­up Or­bis rais­es €90M

I-Mab stops work on CD73; Citius to pur­sue ‘strate­gic’ op­tions

Ex­clu­sive: AI biotech Iambic snags CFO who helped steer Re­cur­sion-Ex­sci­en­tia deal

Oculis’ eye drug clears Phase 2 in France as US de­vel­op­ment beck­ons

A service from the Financial Times